Document is current

Article History

Received: 21 October 2020

Accepted: 12 November 2020

First Online: 15 December 2020

Ethics approval and consent to participate

: The study was approved by the local ethical committee of the university hospital Frankfurt (EK 509/15). Written informed consent from the patient has to be obtained prior to the implantation of any invasive subdural electrodes. If the patient is unable to consent, a patient representative or independent physician may consent on behalf of the patient. Thereafter, if the patient’s clinical situation improves, consent should be sought from them at a later time.

: The consent for publication is integrated in the consent form of patient, which was obtained from every patient as mentioned above.

: <b>S.W.</b> declares no competing interest.<b>T.F.</b> declares no competing interest.<b>P.R.</b> declares no competing interest.<b>D.D.</b> declares no competing interest.<b>E.K.</b> declares no competing interests.<b>E.H.</b> declares no competing interests.<b>V.S.</b> declares no competing interest.<b>F.R.</b> reports personal fees and travel support from UCB, EISAI, Bayer-Vital, Shire,cerbomed, Sandoz, Desitin Arzneimittel, Sage Therapeutics, Novartis Oncology, GW Pharma LMU Munich, Schönkliniken, vfa, research support from the European Union, the Detlev-Wrobel-Fonds for Epilepsy Research the DFG, outside the submitted work.<b>A.S.</b> reports personal fees and grants from Desitin Arzneimittel, Eisai, LivaNova, Sage.Therapeutics, UCB Pharma, and Zogenix, outside the submitted work.<b>J.K.</b> declares no competing interest.